<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03586947</url>
  </required_header>
  <id_info>
    <org_study_id>SAHoWMU-CR2017-07-101</org_study_id>
    <nct_id>NCT03586947</nct_id>
  </id_info>
  <brief_title>Association Between Vitamin D and the Risk of Uterine Fibroids</brief_title>
  <acronym>ABVDATROUF</acronym>
  <official_title>Association Between Vitamin D and the Risk of Uterine Fibroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital of Wenzhou Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this randomised clinical trial study is to evaluate whether supplementation with
      vitamin D could reduce the risk of uterine fibroids in reproductive stage women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 1160 hypovitaminosis D patients (12 ng/ml ≤ serum 25-hydroxyvitamin D3 &lt; 20 ng/ml)
      without uterine fibroids will be randomly assigned in a ratio of 1:1 to two groups:
      intervention group and control group. The intervention group will receive 1600 IU/d of
      vitamin D3; the control group will receive regular follow-up. Patients will be followed up at
      the same time points for 24 months. The outcome measure is the incidence of uterine fibroids
      in different groups.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate of uterine fibroids in different groups</measure>
    <time_frame>two years after treatment</time_frame>
    <description>Incidence rate of uterine fibroids in different groups after two years treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypercalcemia</measure>
    <time_frame>Two years after treatment</time_frame>
    <description>The level of serum calcium &gt; 2.5 mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>abnormal liver function</measure>
    <time_frame>Two years after treatment</time_frame>
    <description>Alanine aminotransferase (ALT) or aspartate transaminase (AST) more than 3 times of the normal upper limit, or total bilirubin (TBIL) more than 2 times of the normal upper limit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>abnormal renal function</measure>
    <time_frame>Two years after treatment</time_frame>
    <description>Creatinine levels≥1.4 mg/dL (123μmol/L) or creatinine clearance ≤ 50 mL/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of uterine fibroids in different groups</measure>
    <time_frame>One year after treatment</time_frame>
    <description>Incidence rate of uterine fibroids in different groups after one year treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1160</enrollment>
  <condition>Gynaecological Disease</condition>
  <condition>Vitamin D Deficiency</condition>
  <condition>Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>Vitamin D3 Drops group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group would take Vitamin D3 400 UNT Oral Capsule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Vitamin D3 Drops group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in this group would take nothing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3 400 UNT Oral Capsule</intervention_name>
    <description>50,000 IU of vitamin D once a week for 8 weeks, 1500-2000 IU/day.</description>
    <arm_group_label>Vitamin D3 Drops group</arm_group_label>
    <other_name>Vitamin D3 drops</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Volunteer to participate in the study with informed consent;

          2. Females aged 35-50 who are confirmed with a normal, fibroid-free uterine structure, by
             means of transvaginal or abdominal ultrasonography;

          3. Serum25-hydroxyvitamin D3 &lt;20 ng/ml, ≥ 12ng/ml.

        Exclusion Criteria:

          1. Use of sexual hormone, mifepristone, gonadotropin-releasing hormone agonist (GnRHa),
             or other medication which is likely to interfere with uterine fibroids within 3
             months;

          2. Pregnancy, lactation, postmenopause, or planned pregnancy within two years;

          3. Allergic to vitamin D3;

          4. Suspected or identified as other tumors of genital tract;

          5. History of hysterectomy or myomectomy;

          6. History of osteoporosis or vitamin D deficiency taking vitamin D supplements within
             previous one month;

          7. History of hyperparathyroidism, infectious diseases (tuberculosis, AIDS), autoimmune
             diseases, or digestive system diseases (malabsorption, crohn disease and dysentery);

          8. Alanine aminotransferase (ALT) or aspartate transaminase (AST) more than 3 times of
             the normal upper limit, total bilirubin (TBIL) more than 2 times of the normal upper
             limit;

          9. Creatinine levels ≥ 1.4 mg/dL (123μmol/L) or creatinine clearance ≤ 50 ml/min;

         10. History of malignant tumors;

         11. Simultaneous participation in another clinical study with investigational medicinal
             product(s) or researcher thinks the subjects are not suitable for this trial.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xueqiong Zhu, PHD</last_name>
    <phone>13906640759</phone>
    <email>zjwzzxq@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>TING LI</last_name>
      <email>feclinicalresearch@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2018</study_first_posted>
  <last_update_submitted>September 3, 2018</last_update_submitted>
  <last_update_submitted_qc>September 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
    <mesh_term>Genital Diseases, Female</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT03586947/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

